Dietary Supplements and Cancer Patients: Use, Tolerance, and Interactions
Official title: Use of Dietary Supplements Among Cancer Patients: Tolerance and Impact on Medications and Drug Interactions Assessed Using the Hedrine Software
Run by Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI) · NCT07670234 · Data updated 2026-11-12
This study looks at how many cancer patients take dietary supplements, how they tolerate them, and whether these supplements interact with cancer treatments.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI) Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Rabat) |
| Status | Recruiting |
| Started | June 1, 2025 |
| Main results expected | June 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | June 26, 2026 |
| Trial ID | NCT07670234 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with cancer receiving anticancer treatment who are using or plan to use dietary supplements.
✕Probably not a fit
Patients not taking or planning to take dietary supplements or those not currently undergoing anticancer therapy may have limited direct benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational study enrolling adults with solid tumor cancers who are receiving anticancer therapy and are using or planning to use dietary supplements. Participants will complete questionnaires about supplement type, frequency, duration, reasons for use, and perceived side effects, along with sociodemographic information. The study will analyze how common supplement use is and explore potential interactions with chemotherapy, targeted therapies, hormone therapy, and immunotherapy. No interventions are applied beyond the assessment of current or recent supplement use, and data will be used to characterize patterns and potential drug– supplement interactions in the context of cancer treatment.
Why it matters
Potential benefit: If successful, findings could guide clinicians and patients on supplement use during cancer therapy and highlight potential interactions to monitor.
How similar studies have gone: Prior observational work in oncology has identified prevalent supplement use and potential interactions, suggesting this approach can yield actionable insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients diagnosed with cancer and receiving medical anticancer treatment, including chemotherapy, hormone therapy, immunotherapy, and targeted therapies. * Current or recent use of one or more dietary supplements (e.g., vitamins, minerals, herbal products, or other nutritional supplements). * Adult patients : \>=18 Exclusion Criteria: * Patients unable to complete the study questionnaire because of cognitive impairment or a deteriorated health condition. * Failure or refusal to provide written informed consent.
Where it's running
-
Institut National d'Oncologie
Rabat, Morocco Recruiting
Study contacts
- Study coordinator: Sihame Lkhoyaali, Professor of Medical Oncology
- Email: slkhoyaali@cm6.ma
- Phone: +212 668-270035
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Steroid-Sparing Plan with Olanzapine and Palonosetron to Prevent Nausea in High-Dose Cisplatin
This phase II trial tests a steroid-sparing regimen using olanzapine and palonosetron to prevent chemotherapy-induced nausea and vomiting in patients getting high-dose cisplatin.
-
SBRT-LATTICE-PATHY for Large Tumors
This trial tests a targeted radiotherapy approach (SBRT-LATTICE-PATHY) to treat large, intractable solid tumors in adults.
-
Does the 1939 Cancer Act still work in the internet and social media age?
This survey asks people treated for cancer and health professionals in England and Wales about online and social media cancer information to see if the 1939 Cancer Act needs updating.
-
TRTRM (ACTTOP) Guided Dosing in Older Cancer Patients
Aims to see if using the TRTRM risk score can help tailor cancer treatment doses for people 65 and older to reduce serious treatment-related toxicities.
-
WellSpan THRIVE Cancer Quality of Life Program
This program will try a patient-focused quality-of-life survey to learn how cancer and its treatments affect adults newly diagnosed with cancer.
-
JMT108 for adults with advanced solid tumors
This trial will try JMT108, a bispecific antibody, in adults with locally advanced or metastatic solid tumors who have exhausted standard treatment options to see if it is safe and shows early signs of benefit.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.